AIDS Therapies (CGP64222)

First Antiviral To Selectively Block Protein/RNA Interaction

Published in AIDS Weekly, May 5th, 1997

A new compound can block HIV replication by interfering with the RNA-binding activity of a viral regulatory protein known as Tat.

Because this is the first report of an antiviral drug that specifically targets a protein/RNA interaction, the discovery represents a novel pharmaceutical approach to antimicrobial and antitumor agents.

The compound, dubbed CGP64222, was created by a researchers at Novartis Ltd. Pharmaceuticals, Basel, Switzerland, and the Medical Research Council, Cambridge, England.

"CGP64222 is to our knowledge the first example of an antiviral compound that selectively inhibits a protein/RNA interaction," wrote...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-05-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry